By integrating bulk RNA-sequencing (TCGA-PRAD), single-cell RNA-sequencing (GEO), and genomic data, we explored the expression characteristics of DOCK3 in prostate cancer and its potential as a therapeutic target. The gene discussed is DOCK3; the disease is Familial prostate cancer.